Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2014BMC Health Services ResearchOpen Access

The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does the initiation of PAH-indicated medication alter health care costs and resource utilization in patients with pulmonary arterial hypertension?

Population

504 subjects with claims-based evidence of PAH in a large US managed care health plan.

Comparison

PAH-indicated medication use vs Annualized baseline period prior to the earliest…

Design

Cohort

Follow-up

12 months

Authors

MSMirko SikiricaAcadia Pharmaceuticals (United States)ŞIŞerban R. IorgaNovartis (Switzerland)TBTim BancroftOptum (United States)

Discussion

Loading...

Member takes

Implication

May support cost savings after PAH therapy start; leaves open need for randomized confirmation of utilization changes.

Structured PICO

Does the initiation of PAH-indicated medication alter health care costs and resource utilization in patients with pulmonary arterial hypertension?

P
Population
504 subjects with claims-based evidence of PAH (≥2 claims with primary PH diagnosis, ≥2 claims with PAH related-diagnosis, and ≥1 claim with evidence of a PAH-indicated medication) in a large US managed care health plan.
I
Intervention
PAH-indicated medication use (12-month follow-up period after index claim)
C
Comparator
Annualized baseline period prior to the earliest claim for PAH-indicated medication
O
Outcome
Health care costs and resource utilization

In patients with PAH, the initiation of disease-specific medications is associated with a significant reduction in overall healthcare costs, driven by decreased medical utilization despite higher pharmacy expenses.

Limitations

  • Results varied in exploratory analyses when less restrictive subject identification algorithms were used

Cite This Study

Sikirica et al. (2014) studied this question.

synapsesocial.com/papers/6a8d45da0d3f49ce2d7fe729https://doi.org/10.1186/s12913-014-0676-0

Topics

Hypertension management
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States2011 · 64 citations
  2. 2Opioid Abuse in the United States and Department of Health and Human Services Actions to Address Opioid-Drug-Related Overdoses and Deaths2015 · 891 citations
  3. 32009 ESC/ERS Pulmonary Hypertension Guidelines and Connective Tissue Disease2011 · 24 citations
  4. 4Comprehensive MDCT Evaluation of Patients With Pulmonary Hypertension: Diagnosing Underlying Causes With the Updated Dana Point 2008 Classification2011 · 16 citations